文献速递胸部肿瘤

地舒单抗联合一线化疗治疗晚期非小细胞肺癌的III期随机试验

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
PubMed 文献 · J Thorac Oncol · 2020-06-18

SPLENDOUR试验评估在晚期非小细胞肺癌标准一线铂类双药化疗基础上加用地舒单抗能否改善总生存。共随机514例患者,因入组缓慢提前终止。结果显示化疗联合地舒单抗组与单纯化疗组中位OS分别为8.2个月和8.7个月(HR=0.96,95%CI 0.78-1.19,单侧p=0.36),无生存获益,骨转移亚组亦无获益,但安全性可接受。

要点

  • 在晚期NSCLC一线化疗中加用地舒单抗未改善总生存。
  • 骨转移亚组HR=1.02,无骨转移亚组HR=0.90,均无显著获益。
  • 地舒单抗耐受性良好,≥3级不良事件发生率与对照组相近。

核心结论

  • 在晚期NSCLC患者中,化疗联合地舒单抗对比单纯化疗未改善总生存,骨转移和无骨转移亚组均无获益,不支持地舒单抗在该人群中的临床获益。

研究设计与样本

  • 随机开放标签III期SPLENDOUR试验,纳入IV期NSCLC患者,1:1随机分配至化疗联合或不联合地舒单抗(120 mg每3-4周),按骨转移、ECOG PS、组织学和地区分层。

主要发现

  • 共514例患者随机,509例接受至少一剂治疗(化疗组252例,化疗联合地舒单抗组257例)。
  • 中位年龄66.1岁,男性占71%,既往吸烟者占59%,骨转移患者275例(53%)。
  • 中位OS在对照组为8.7个月(95%CI 7.6-11.0),联合组为8.2个月(95%CI 7.5-10.4),HR=0.96(95%CI 0.78-1.19),单侧p=0.36。
  • 骨转移患者HR=1.02(95%CI 0.77-1.35),无骨转移患者HR=0.90(95%CI 0.66-1.23)。
  • ≥3级不良事件发生率在化疗组、地舒单抗组和联合组分别为40.9%、5.2%、8.7%和45.5%、10.9%、10.5%。

临床怎么用

  • 不推荐在晚期NSCLC一线铂类化疗中常规加用地舒单抗以改善生存。

局限性

  • 试验因入组率下降提前终止,实际样本量(514例)低于计划检测OS获益所需的847例事件数,统计效力不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Receptor activator of NF-kB ligand stimulates NF-kB-dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysis of a large trial comparing denosumab versus zoledronic acid in bone metastatic solid tumors suggested significant overall survival (OS) advantage for patients with lung cancer with denosumab (p = 0.01). The randomized open-label phase III SPLENDOUR trial was designed to evaluate whether the addition of denosumab to standard first-line platinum-based doublet chemotherapy improved OS in advanced NSCLC. METHODS: Patients with stage IV NSCLC were randomized in a 1:1 ratio to either chemotherapy with or without denosumab (120 mg every 3-4 wks), stratified by the presence of bone metastases (at diagnosis), Eastern Cooperative Oncology Group performance status, histology, and region. To detect an OS increase from 9 to 11.25 months (hazard ratio [HR] = 0.80), 847 OS events were required. The trial closed prematurely owing to decreasing accrual rate. RESULTS: A total of 514 patients were randomized, with 509 receiving one or more doses of the assigned treatment (chemotherapy: 252, chemotherapy-denosumab: 257). The median age was 66.1 years, 71% were men, and 59% were former smokers. Bone metastases were identified in 275 patients (53%). Median OS (95% confidence interval [CI]) was 8.7 (7.6-11.0) months in the control arm versus 8.2 (7.5-10.4) months in the chemotherapy-denosumab arm (HR = 0.96; 95% CI: 0.78-1.19; one-sided p = 0.36). For patients with bone metastasis, HR was 1.02 (95% CI: 0.77-1.35), whereas for those without, HR was 0.90 (95% CI: 0.66-1.23). Adverse events grade 3 or greater were observed in 40.9%, 5.2%, 8.7% versus 45.5%, 10.9%, 10.5% of patients. Conditional power for OS benefit was less than or equal to 10%. CONCLUSIONS: Denosumab was well-tolerated without unexpected safety concerns. There was no OS improvement for denosumab when added to chemotherapy in the intention-to-treat population and the subgroups with and without bone metastases. Our data do not provide evidence of a clinical benefit for denosumab in patients with NSCLC without bone metastases.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Danson S, Hasan B, et al. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. J Thorac Oncol. 2020. PMID: 32565388. doi:10.1016/j.jtho.2020.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。